Updated 04:01 GMT, 8 Nov 2026 SPX 7,376.86 +0.31% NDX 26,989.99 +1.35% VIX 25.64 -9.01% GOLD 4,074.90 -0.94% CL 90.83 +0.34% BTC 75,817.70 +0.09%
NAS100 26,990 +1.35% S&P 7,377 +0.31% GOLD $4,075 −0.94% BTC $75,818 +0.09% VIX 25.64 −9.01% prices · as of 04:01 UTC
Vol. II · No. 312Sunday, 8 November 2026
TTitan Protect
Case Studies · Earnings Echo

Regeneron Pharmaceuticals: What the Print Has to Prove Today

Filed Friday 30 October 2026 · 13:01 UTC · Entry no. 133036 · scored against the close · never edited

Regeneron Pharmaceuticals: What the Print Has to Prove Today
Earnings Preview · 30 October 2026
Where our screen stands going in
Screens compliant (both standards agree). A name values-conscious investors can weigh on the merits.
What the Street expects
Consensus looks for earnings of about $16.25 a share on revenue near $4.6B. Over the next twelve months analysts pencil in $62.82 of earnings per share against $40.44 over the last twelve, growth of about 55%. The median analyst target is $900 (range $730 to $1030), 2% above the $886.00 share price, across 27 analysts.
How it has traded on past prints
Across the last 25 reports, the shares moved an average of -0.1% in the five sessions after the print and +0.9% over twenty. After a beat the average follow-through was +0.7%; after a miss, +3.9%. Misses have not been punished more than beats were rewarded, so the headline number alone has been a poor guide to the reaction here; guidance and the call matter more. There is no reliable drift pattern: the first move has often faded, so chasing the gap has not paid.
Levels that matter
At $886.00 the shares sit -3% below the 52-week high of $859.34 and 50% above the low of $591.52 (110% of the way up the range). The 50-day average is $791.38, below the price. The 200-day average is $735.37, below the price.
Valuation going in
The shares trade about 14% below our fair-value estimate: a modest cushion. Our fair-value estimate is $1030.00 against the current share price of $886.00. The shares trade at 20.2 times trailing earnings and 13.0 times forward earnings. Revenue is growing about 17% with net margins near 28%.
Our stance
The name clears our screen; the print tells us whether the valuation is earning its keep.
What the flow says going in
Money has been flowing IN underneath a flat-to-lower price: quiet accumulation, the kind of positioning that tends to show up before a name moves, not after. (21-day Chaikin Money Flow +0.05, five-day price change -0.0%, as of 2026-10-29, desk flow model).

This is analysis, not financial advice. Always manage your risk.

How This Entry Scores

Every level named in a session brief is scored against the next scheduled close. Nothing is edited after filing: if a level breaks, the record shows it as filed, not as corrected. The desk's full scored history sits on the track record page.

Continue Reading View all Case Studies →
Membership

The ledger is public. The desk behind it is not.

Membership opens every room and every entry the day it is filed, with the same dated honesty the record is built on.

Join the desk

This is analysis, not financial advice. Always manage your risk.

Get our weekly market brief free.